When the state withdraws, the marketplace arrives

THE LAUNCH of POST™ in late July 2026 is being presented as an innovation. It is, more accurately, a symptom. The Academic Orthopaedic Consortium (AOC), a group representing more than 200 university-based orthopaedic departments, has unveiled a digital platform connecting those departments with medtech and pharmaceutical companies for technology evaluation, research and education. Forty-six departments have already appointed Technology Evaluation Leaders. Seven founding industry partners - including Stryker, Smith+Nephew, Arthrex and DePuy Synthes - have signed on. The platform is governed by a "Badge of Excellence" framework meant to preserve academic independence. It is a tidy arrangement. The trouble is that it would not exist without the collapse of public research funding.

For decades, the National Institutes of Health was the engine of American biomedical research. In 2025 and 2026, that engine sputtered. The administration froze or terminated more than $3 billion in approved grants from the NIH and the National Science Foundation. In February 2025, the NIH proposed capping "indirect costs" - the overhead reimbursement that covers laboratories, utilities, data processing and patient safety - at 15%. The average indirect-cost rate across universities is far higher; the cap would have shaved $6.5 billion from the research enterprise. A lawsuit by the Association of American Medical Colleges halted the measure temporarily, but the administration has signalled its intention to pursue it in the fiscal 2026 budget, which also proposes $18 billion in NIH cuts. By May 2026, the Trump administration had removed the entire board of advisers overseeing the National Science Foundation, as the Brennan Center for Justice at NYU Law documents.

The consequence for academic orthopaedics is direct. University departments that once relied on federal grants to fund technology evaluation, clinical trials and resident training are suddenly short of cash. Meanwhile, the companies developing the next generation of orthopaedic devices need academic centres to validate their products. The orthopaedic market was approximately $62 billion globally in 2025, with implants accounting for $53 billion, according to Gabelli & Co, an investment firm. Stryker alone spent $1.5 billion on research and development in its latest fiscal year, up 6%. Yet aggregate R&D spending across the Medtech Big 100 grew less than 1% in 2025, after double-digit increases in the preceding two years, as Medical Design & Outsourcing reports. Revenue was at a record $486.7 billion. Companies are not stopping innovation; they are optimising it. And optimisation means finding efficient pathways to evidence, regulation and adoption.

POST is the bridge between these two realities. Academic departments post their research capacity and evaluation needs; companies post opportunities for collaboration, validation studies and education. The AOC describes the platform as bi-directional, allowing departments to shape the innovation agenda rather than merely respond to it. The Badge of Excellence framework sets participation criteria and ethical guardrails. It is a reasonable attempt to structure what is essentially a market in evidence generation.

To be sure, the arrangement is not inherently corrupt. Academic medicine and industry have collaborated since the beginning of modern device development. The FDA requires clinical evidence for most new orthopaedic implants and systems. Universities have the surgeons, patients and research infrastructure that companies lack. The reverse is also true: companies have capital, regulatory expertise and distribution channels. A platform that makes collaboration more transparent and efficient could reduce duplication, shorten evaluation timelines and bring validated technology to patients faster. The AOC's MedTech Advisory Council, which shaped the platform over two years, identified wide variability in how departments evaluate new technology. Standardising that process has merit.

Yet the structural change is not the platform itself. It is the withdrawal of the state from public research funding. When the NIH funded university research, the research agenda was set by a mix of scientific merit, public health priorities and institutional peer review. When the NIH retreats, the agenda shifts toward whatever the private sector is willing to pay for. That is not a conspiracy. It is an arithmetic. Academic departments whose overhead budgets have been gutted will find it difficult to say no to companies that can fund their operations. The incentive to collaborate is no longer merely scientific curiosity. It is institutional survival.

The deeper problem is not that collaboration will stop being honest. It is that it will stop being independent. Academic departments that rely on medtech funding for their research enterprises will gravitate toward projects that companies want evaluated - the latest robotic knee system, the newest spinal stimulator, the proprietary biomaterial. They will be less likely to study what the evidence actually needs: whether those technologies are better than what already exists, at what cost, and for which patients. Comparative-effectiveness research is unfashionable in industry because it threatens incumbents as well as newcomers. It will be unfashionable in industry-funded academic departments for the same reason.

The second-order effect is regulatory. The FDA has increasingly relied on real-world evidence and industry-sponsored trials to approve devices. If the academic evaluation pipeline itself becomes industry-dependent, the evidentiary base for regulation becomes circular. Companies fund the research that validates their products, which then supports regulatory approval, which justifies the spending. The system is not broken so much as captured. The Badge of Excellence, for all its guardrails, cannot reverse the underlying incentive. A seal of quality does not change the fact that the funder sets the agenda.

For investors in orthopaedic companies, the platform signals a maturation of the evidence-generation pipeline. Stryker, Smith+Nephew, Arthrex and the others on the founding list now have a structured channel to academic evaluation that was previously informal, relationship-dependent and slow. That is a competitive advantage for participants and a mild moat against newcomers. But the same dynamics that make POST attractive - the funding vacuum - also mean that evidence produced through the platform will carry an implicit question mark. Regulators, payers and sophisticated hospital procurement teams may discount industry-aligned academic research in the same way they already treat manufacturer-sponsored data. The platform's value will depend on whether the research it generates is credible enough to influence purchasing decisions, reimbursement rates and market share.

The better answer is not to romanticise public funding or to dismiss industry collaboration. It is to structure the relationship so that academic independence is preserved even as private money flows in. AOC's guardrails are a start. What is needed is more: blinded study designs, independent data committees, pre-registered protocols, and a separation between funding and editorial control over publication. Some of these mechanisms already exist in pharmaceutical trials. Orthopaedics has been slower to adopt them. The platform should require them rather than merely encourage them.

The broader lesson extends beyond orthopaedics. The withdrawal of federal research funding is not limited to one specialty. It affects cardiology, oncology, neurology and every field that depends on university laboratories. Private capital is filling the gap, and platforms like POST will multiply. That is the market doing what markets do. But evidence generation is not an ordinary commodity. It is the infrastructure on which clinical decisions, regulatory approvals and public health depend. Treating it as a product to be traded efficiently is not wrong. It is incomplete. The state's retreat from research funding may be politically irresistible. It should not be scientifically accepted.

A digital platform for industry-academic collaboration is a sensible response to a terrible incentive. Fix the incentive first.